216 related articles for article (PubMed ID: 33627489)
1. Mechanism and reversal of drug-induced nephrotoxicity on a chip.
Cohen A; Ioannidis K; Ehrlich A; Regenbaum S; Cohen M; Ayyash M; Tikva SS; Nahmias Y
Sci Transl Med; 2021 Feb; 13(582):. PubMed ID: 33627489
[TBL] [Abstract][Full Text] [Related]
2. Aminoglycoside-induced lipotoxicity and its reversal in kidney on chip.
Ioannidis K; Cohen A; Ghosheh M; Ehrlich A; Fischer A; Cohen M; Nahmias Y
Lab Chip; 2022 Nov; 22(23):4469-4480. PubMed ID: 36281785
[TBL] [Abstract][Full Text] [Related]
3. Nephrotoxicity and Kidney Transport Assessment on 3D Perfused Proximal Tubules.
Vormann MK; Gijzen L; Hutter S; Boot L; Nicolas A; van den Heuvel A; Vriend J; Ng CP; Nieskens TTG; van Duinen V; de Wagenaar B; Masereeuw R; Suter-Dick L; Trietsch SJ; Wilmer M; Joore J; Vulto P; Lanz HL
AAPS J; 2018 Aug; 20(5):90. PubMed ID: 30109442
[TBL] [Abstract][Full Text] [Related]
4. 3D Cell Printing of Advanced Vascularized Proximal Tubule-on-a-Chip for Drug Induced Nephrotoxicity Advancement.
Singh NK; Kim JY; Jang J; Kim YK; Cho DW
ACS Appl Bio Mater; 2023 Sep; 6(9):3750-3758. PubMed ID: 37606916
[TBL] [Abstract][Full Text] [Related]
5. Role of sodium/glucose cotransporter inhibition on a rat model of angiotensin II-dependent kidney damage.
Reyes-Pardo H; Bautista R; Vargas-Robles H; Rios A; Sánchez D; Escalante B
BMC Nephrol; 2019 Aug; 20(1):292. PubMed ID: 31375080
[TBL] [Abstract][Full Text] [Related]
6. SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice.
Vallon V; Gerasimova M; Rose MA; Masuda T; Satriano J; Mayoux E; Koepsell H; Thomson SC; Rieg T
Am J Physiol Renal Physiol; 2014 Jan; 306(2):F194-204. PubMed ID: 24226524
[TBL] [Abstract][Full Text] [Related]
7. Optimizing SGLT inhibitor treatment for diabetes with chronic kidney diseases.
Layton AT
Biol Cybern; 2019 Apr; 113(1-2):139-148. PubMed ID: 29955959
[TBL] [Abstract][Full Text] [Related]
8. A Multicompartment Human Kidney Proximal Tubule-on-a-Chip Replicates Cell Polarization-Dependent Cisplatin Toxicity.
Nieskens TTG; Persson M; Kelly EJ; Sjögren AK
Drug Metab Dispos; 2020 Dec; 48(12):1303-1311. PubMed ID: 33020068
[TBL] [Abstract][Full Text] [Related]
9. Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia.
Rieg T; Masuda T; Gerasimova M; Mayoux E; Platt K; Powell DR; Thomson SC; Koepsell H; Vallon V
Am J Physiol Renal Physiol; 2014 Jan; 306(2):F188-93. PubMed ID: 24226519
[TBL] [Abstract][Full Text] [Related]
10. Effects of SGLT2 inhibition in human kidney proximal tubular cells--renoprotection in diabetic nephropathy?
Panchapakesan U; Pegg K; Gross S; Komala MG; Mudaliar H; Forbes J; Pollock C; Mather A
PLoS One; 2013; 8(2):e54442. PubMed ID: 23390498
[TBL] [Abstract][Full Text] [Related]
11. Organic anion transporter OAT3 enhances the glucosuric effect of the SGLT2 inhibitor empagliflozin.
Fu Y; Breljak D; Onishi A; Batz F; Patel R; Huang W; Song P; Freeman B; Mayoux E; Koepsell H; Anzai N; Nigam SK; Sabolic I; Vallon V
Am J Physiol Renal Physiol; 2018 Aug; 315(2):F386-F394. PubMed ID: 29412698
[TBL] [Abstract][Full Text] [Related]
12. Interplay of adenosine monophosphate-activated protein kinase/sirtuin-1 activation and sodium influx inhibition mediates the renal benefits of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes: A novel conceptual framework.
Packer M
Diabetes Obes Metab; 2020 May; 22(5):734-742. PubMed ID: 31916329
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the urinary glucose excretion contributions of SGLT2 and SGLT1: A quantitative systems pharmacology analysis in healthy individuals and patients with type 2 diabetes treated with SGLT2 inhibitors.
Yakovleva T; Sokolov V; Chu L; Tang W; Greasley PJ; Peilot Sjögren H; Johansson S; Peskov K; Helmlinger G; Boulton DW; Penland RC
Diabetes Obes Metab; 2019 Dec; 21(12):2684-2693. PubMed ID: 31423699
[TBL] [Abstract][Full Text] [Related]
14. Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level.
Katsuno K; Fujimori Y; Takemura Y; Hiratochi M; Itoh F; Komatsu Y; Fujikura H; Isaji M
J Pharmacol Exp Ther; 2007 Jan; 320(1):323-30. PubMed ID: 17050778
[TBL] [Abstract][Full Text] [Related]
15. [Role of the kidneys in glucose homeostasis. Implication of sodium-glucose cotransporter 2 (SGLT2) in diabetes mellitus treatment].
Girard J
Nephrol Ther; 2017 Apr; 13 Suppl 1():S35-S41. PubMed ID: 28577741
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of Protective Effects of SGLT2 Inhibitors in Cardiovascular Disease and Renal Dysfunction.
Liu B; Wang Y; Zhang Y; Yan B
Curr Top Med Chem; 2019; 19(20):1818-1849. PubMed ID: 31456521
[TBL] [Abstract][Full Text] [Related]
17. Sodium-glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus.
Neumiller JJ; White JR; Campbell RK
Drugs; 2010 Mar; 70(4):377-85. PubMed ID: 20205482
[TBL] [Abstract][Full Text] [Related]
18. SGLT2 inhibition and renal urate excretion: role of luminal glucose, GLUT9, and URAT1.
Novikov A; Fu Y; Huang W; Freeman B; Patel R; van Ginkel C; Koepsell H; Busslinger M; Onishi A; Nespoux J; Vallon V
Am J Physiol Renal Physiol; 2019 Jan; 316(1):F173-F185. PubMed ID: 30427222
[TBL] [Abstract][Full Text] [Related]
19. Drug transporter expression profiling in a three-dimensional kidney proximal tubule in vitro nephrotoxicity model.
Diekjürgen D; Grainger DW
Pflugers Arch; 2018 Sep; 470(9):1311-1323. PubMed ID: 29744639
[TBL] [Abstract][Full Text] [Related]
20. Cardioprotection conferred by sodium-glucose cotransporter 2 inhibitors: a renal proximal tubule perspective.
Silva Dos Santos D; Polidoro JZ; Borges-Júnior FA; Girardi ACC
Am J Physiol Cell Physiol; 2020 Feb; 318(2):C328-C336. PubMed ID: 31721613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]